PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for PMCB. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: PMCB is a Sell candidate.
PMCB stock price ended at $0.72 on 星期三, after dropping 7.69%
On the latest trading day Feb 11, 2026, the stock price of PMCB fell by 7.69%, dropping from $0.79 to $0.72. During the session, the stock saw a volatility of 12.68%, with prices oscillating between a daily low of $0.71 and a high of $0.80. On the latest trading day, the trading volume for PMCB rose by 91.9K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 148.8K shares were traded, with a market value of approximately $4.8M.